Suzanne C. van Es

⁸⁹Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment

Sjoukje F. Oosting, Adrienne H. Brouwers, Suzanne C. van Es et al. · Journal of Nuclear Medicine · 2014 · 114 citations · Full text

Medicine, Oncology, Pharmacology +17

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Sarah R. Verhoeff, Suzanne C. van Es, Eline Boon et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 107 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Comparative biodistribution analysis across four different ⁸⁹Zr-monoclonal antibody tracers—The first step towards an imaging warehouse

Frederike Bensch, Michaël M. Smeenk, Suzanne C. van Es et al. · Theranostics · 2018 · 65 citations · Full text

Medicine, Nuclear Medicine, Pharmacology +17

⁸⁹Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma

Suzanne C. van Es, Adrienne H. Brouwers, Shekar V.K. Mahesh et al. · Journal of Nuclear Medicine · 2017 · 57 citations · Full text

Medicine, Oncology, Pharmacology +16

<i><scp>RAS</scp></i> and <i><scp>BRAF</scp></i> mutations in cell‐free <scp>DNA</scp> are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested <i><scp>RAS</scp></i> wild‐type advanced colorectal cancer

Erik J. van Helden, Lindsay Angus, C. Willemien Menke‐van der Houven van Oordt et al. · Molecular Oncology · 2019 · 54 citations · Full text

Medicine, Oncology, Cancer Genetics +16